News NICE update doubles eligible patients for AZ's Lokelma AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
News Diagnostics lag is holding back new therapies, says study Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
News NHS risks missing out on independent prescriber benefits Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.
News AbbVie tries a new approach in 340B programme battle AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
News 23andMe study explains variable results with obesity drugs Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
News US judge blocks bid to curb abortion pill access A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been blocked in the courts.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
